Objective: The aim of the present study was to prospectively evaluate the effect of aclatonium on dry mouth in patients with overactive bladder (OAB) after treatment with solifenacin.
cholinergic drug that increases saliva production. A recent study showed that a combination of tolterodine and pilocarpine reduced the incidence of dry mouth compared with tolterodine alone. 6 Aclatonium is another synthesized cholinergic drug used to increase motility and peristalsis in the gastrointestinal tract. 7 Hypersecretion of saliva is a well-known side effect of aclatonium, which could decrease dry mouth during antimuscarinic therapy, as seen with pilocalpine. 7 However, to date no study has investigated the effect of aclatonium on dry mouth during antimuscarinic therapy. Thus, the aim of the present study was to prospectively evaluate the effects of aclatonium on dry mouth in patients with OAB after 8 weeks treatment with solifenacin.
2 | METHODS
| Patients and study design
The present 8-week multicenter randomized double-blind controlled trial was conducted at 3 sites in Korea. The study protocol was reviewed and approved by the institutional review board at each study center, and the study was conducted in accordance with the Declaration of Helsinki.
The study subjects were men and women >18 years of age who had been diagnosed with OAB for ≥3 months and presented with a total Overactive Bladder Symptom Score (OABSS) ≥3. Patients with the following conditions were excluded from the study: post-void residual urine volume >150 mL; a history of intestinal hernia or lower urinary tract surgery within the past 6 months; acute urinary tract infection; use of an indwelling catheter or self-catheterization; or antimuscarinic use within 3 months of baseline. Eligible subjects were randomized to receive 5 mg solifenacin with placebo or 5 mg solifenacin with 150 mg aclatonium orally, once daily after breakfast, for 8 weeks. Randomization was accomplished using a computergenerated randomization scheme with stratification by site.
Study visits took place during Week 0 (Visit 1; confirmation of eligibility criteria), Week 4 (Visit 2), and Week 8 (Visit 3; follow-up visit and the end of the treatment). Subjects rated dry mouth using a visual analog scale (VAS) and completed the Bristol stool chart, 8 the OAB-questionnaire (OAB-q) short form (SF) questionnaire 9 and the OABSS questionnaire 10 at baseline (Week 0) and at Week 8 ( Figure 1 ).
The degree of dry mouth was evaluated using a VAS (range 0-100 points), with dry mouth defined as a VAS score >30 points.
Patients were divided into 2 subgroups (no dry mouth and dry mouth subgroups) according to dry mouth status at baseline.
| Efficacy outcome measures
The primary efficacy endpoint was change in dry mouth VAS score from baseline to the final visit. Secondary efficacy endpoints were changes in OAB symptoms, as measured by the OABSS and the OAB-q SF questionnaires, from baseline to the final visit.
| Sample size
A sample size of 144 patients provided 90% power to compare the combined drug treatment with single drug treatment with a 2-sided significance level of 5%. Sample size was calculated based on the assumption of a 25% decrease on the VAS being significant. Considering a 20% dropout rate, the target number of randomized patients was set at 72 patients per group.
| Statistical analysis
Statistical analyses were performed using PASW version 17.0 software (SPSS Inc., Chicago, IL, USA). Changes in the dry mouth VAS and OAB-q SF scores and OABSS were compared between groups using Student's t-tests and the Mann-Whitney U-test. Categorical data were analyzed using the Chi-squared test. The reported P-values were two-sided, and P < .05 was considered significant.
| RESULTS

| Baseline demographics
In all, 161 patients were randomized to receive solifenacin + placebo Demographic characteristics, baseline OAB symptoms, and the degree of dry mouth, as measured using the VAS, were similar between the placebo and aclatonium groups (Table 1) .
| Overall patients
Both the placebo and aclatonium groups showed a significant decrease in OAB symptoms after 8 weeks treatment. In the placebo group, there was a 3.5-and 5.4-point decrease from baseline in the OABSS and OAB-q SF scores, respectively. In the aclatonium group, there was a 3.7-and 5.0-point decrease from baseline in the OABSS and the OAB-q SF scores, respectively. There was no significant difference in the decrease in symptom scores between the 2 groups (Table 2 ).
No significant difference was detected in changes in dry mouth VAS scores between the 2 groups, with the placebo and aclatonium groups showing 15-and 9-point increases on the dry mouth VAS, respectively (P = .24; Figure 2A ). The proportion of patients with dry mouth (VAS score >30 points) was also similar between the placebo and aclatonium groups (62% vs. 51%, respectively).
| Patients with dry mouth at baseline
Based on VAS score, 31 patients had dry mouth at baseline (12 in the placebo group, 19 in the aclatonium group). There was no significant difference in the proportion of patients with dry mouth patients Unless indicated otherwise, data are presented as the mean AE SD or as n (%). †Dry mouth VAS is presented as the mean score.
BMI, body mass index; OBASS, Overactive Bladder Symptom Score; OAB-q SF, OAB-questionnaire Short Form; VAS, visual analog scale. between the 2 groups (92% vs. 84% in the placebo and aclatonium groups, respectively). The effects of aclatonium treatment on dry mouth in patients with dry mouth at baseline did not differ significantly from those of placebo. In the placebo group, there was a 5-point increase in the dry mouth VAS score, compared with a 7-point increase in the aclatonium group (P = .21; Figure 2B ). There were significant decreases in OABSS and OAB-q SF scores compared with baseline in both groups, but the difference between the 2 groups was not significant (Table 2 ).
| Patients without dry mouth at baseline
Based on the VAS score, 51 patients did not have dry mouth at baseline (27 in the placebo group, 24 in the aclatonium group). After 8 weeks treatment, the change in the dry mouth VAS score was significantly lower in the aclatonium than placebo group: the VAS score increased 20 points in the placebo group, compared with 9 points in the aclatonium group (P = .03; Figure 2C ). Although approximately half the patients (48%) in the placebo group complained of dry mouth (VAS score >30) after treatment, only one-quarter of patients (25%) in the aclatonium group complained of dry mouth.
There was a significant decrease in OAB symptoms compared with baseline in both groups, with no significant differences between them ( Table 2 ).
| DISCUSSION
Anticholinergics are the main treatment modality for OAB, but their use is associated with side effects such as dry mouth, constipation, and blurred vision. Dry mouth is particularly bothersome for patients and may be the most common and problematic side effect of antimuscarinic therapy, occurring in up to 70% of patients. 11 One study showed that dry mouth occurs or is aggravated in 29.2% of patients with OAB with or without dry mouth before solifenacin treatment.
12
Dry mouth is the main cause for discontinuing treatment. 13 Considering that only 20% of OAB patients persist with anticholinergic medication beyond 1 year, 14 reducing the incidence of dry mouth is important in increasing treatment efficacy and compliance for patients with OAB who are on anticholinergics. 15 To decrease the occurrence of dry mouth during treatment, life style modifications, such as chewing sugar-free gum, eating more fiber, and using a mouth wash, have been recommended. Mirabegron is a new β-adrenoceptor agonist with good efficacy and a low rate of dry mouth. 16, 17 Taking medication to stimulate the salivary glands is another option to reduce the occurrence of dry mouth. Pilocarpine and cevimeline increase saliva production. Aclatonium napadisilate, a synthetic choline ester, increases the motility and peristalsis of the gastrointestinal tract by activating muscarinic cholinergic receptors on smooth muscle of the digestive tract. 18 The stimulatory effects of aclatonium napadisilate on digestive enzyme secretion provide additional benefits to treat various gastrointestinal disorders. 18 Aclatonium also increases salivary flow, which could decrease dry mouth in patients taking anticholinergics. As another option, topical application of a cholinesterase inhibitor, such physostigmine, could be an effective treatment of dry mouth. 19 The results of the present study show that combination treatment with aclatonium and solifenacin significantly decreased dry mouth compared with solifenacin alone in patients who did not have dry mouth before starting treatment. This demonstrates the efficacy of aclatonium in reducing dry mouth in patients using anticholinergics.
However, the effect of the combined aclatonium and solifenacin treatment was not significant in patients who already had dry mouth before starting treatment, possibly because these patients had an underlying pathological problem in the salivary gland, so the aclatonium did not work well.
No differences were seen between the single-drug and combination treatment groups with regard to improvements in OAB symptoms, suggesting that aclatonium does not have a negative effect on OAB symptoms.
The present study has several limitations. First, the study was a prospective randomized study, but the total number of study subjects was low due to a high dropout rate. This may be due to unexpected side effects of the anticholinergic drug. The second limitation of the FIGURE 2 Changes in dry mouth scores (mean values) on the visual analog scale (VAS) from baseline over 8 weeks treatment with either aclatonium and solifenacin in combination or solifenacin alone (+ placebo) in A, all study patients, B, patients with a dry mouth at baseline (VAS >30), and C, patients without a dry mouth at baseline study is the relatively short duration of treatment. Aclatonium is not a well known drug and its effects on salivation have not been well studied.
However, the present multicenter prospective randomized study did demonstrate the efficacy of aclatonium in preventing dry mouth in patients who did not have dry mouth before starting treatment for OAB. These findings could be applicable to patient management to prevent dry mouth associated with anticholinergic treatment.
In conclusion, aclatonium decreased dry mouth without affecting treatment efficacy in patients who did not have dry mouth before starting treatment. These findings could provide physicians and patients with another useful option to prevent dry mouth during anticholinergic treatment.
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